Low levels of all three genes are associated with TNBC subtype, malignancy and poor prognosis for breast cancer patients, in line with previous reports for MAPT [25,26] and MTUS1 [16,17], MAST4 being much less studied. This evidence concerns the gene MTUS1 and breast carcinoma.